8-K: Corcept Reports Strong 2025 Revenue, Advances Clinical Pipeline

Corcept Therapeutics announced full-year 2025 revenue of $761.4 million, provided 2026 revenue guidance, and detailed significant progress across its clinical development programs.

Summary

• Full-year 2025 revenue reached $761.4 million, an increase from $675.0 million in 2024.
• Fourth quarter 2025 revenue was $202.1 million, up from $181.9 million in Q4 2024.
• Full-year 2025 net income decreased to $99.7 million ($0.82 diluted EPS) from $141.2 million ($1.23 diluted EPS) in 2024.
• Cash and investments stood at $532.4 million as of December 31, 2025, down from $603.2 million at December 31, 2024.
• The company repurchased $245.9 million of its common stock in 2025.
• 2026 revenue guidance is projected to be between $900 million and $1,000 million.
• The Cushing's syndrome business saw a 37% increase in tablets sold in 2025, driven by record new prescriptions and prescribers, despite Q4 operational disruptions.
• The transition to a new specialty pharmacy is complete, with February 2026 on track for a record number of new patients.
• Relacorilant's NDA for platinum-resistant ovarian cancer has a PDUFA date of July 11, 2026, and the MAA for Europe is expected to be approved by the end of 2026.
• Key clinical trial results are expected in 2026 for MOMENTUM (resistant hypertension), BELLA Part A (ovarian cancer), and MONARCH (MASH).
• A Phase 3 trial for dazucorilant in ALS is planned to begin by mid-2026, following promising Phase 2 results showing an 84% reduction in risk of death in the first year for the 300mg dose.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive update. While profitability metrics declined and there were operational disruptions, the strong revenue growth, robust 2026 guidance, and significant clinical pipeline advancements, particularly in oncology and ALS, outweigh the short-term financial dips and operational hurdles.

Positives

• Full-year 2025 revenue increased to $761.4 million from $675.0 million in 2024.
• Fourth quarter 2025 revenue increased to $202.1 million from $181.9 million in Q4 2024.
• 2026 revenue guidance of $900 million to $1,000 million indicates strong expected growth.
• Cushing's syndrome business experienced a 37% increase in tablets sold in 2025, with record new prescriptions and prescribers.
• The transition to a new specialty pharmacy is complete, and February 2026 is projected to be a record month for new patient starts in Cushing's syndrome.
• Relacorilant's NDA for platinum-resistant ovarian cancer has a PDUFA date of July 11, 2026, and the MAA for Europe is expected to be approved by the end of 2026.
• The ROSELLA study for relacorilant in platinum-resistant ovarian cancer met both dual primary endpoints (progression-free and overall survival), showing a 35% reduction in the risk of death without increased safety burden.
• Results from the MOMENTUM trial (hypercortisolism in resistant hypertension) will be presented at the ACC meeting in March.
• Promising exploratory analyses from the DAZALS study for dazucorilant in ALS showed an 84% reduction in the risk of death during the first year for patients receiving 300 mg.
• Enrollment completed for MONARCH (MASH) and BELLA Part A (platinum-resistant ovarian cancer) trials, with results expected by the end of 2026.
• Relacorilant has the potential to become the new standard of care for patients with Cushing's syndrome, showing clinically meaningful and statistically significant improvements without off-target effects.

Negatives

• Full-year 2025 net income decreased to $99.7 million from $141.2 million in 2024.
• Fourth quarter 2025 net income decreased to $24.3 million from $30.7 million in Q4 2024.
• Diluted net income per common share for 2025 decreased to $0.82 from $1.23 in 2024.
• Cash and investments decreased to $532.4 million at December 31, 2025, from $603.2 million at December 31, 2024.
• The company was not able to fully meet demand for its Cushing's syndrome medications due to capacity constraints at its previous specialty pharmacy vendor.
• Operational disruptions occurred in the fourth quarter of 2025 during the transition to a new specialty pharmacy.
• Relacorilant's NDA for Cushing's syndrome received a Complete Response Letter, requiring further engagement with the FDA to determine the best path forward for approval.

Risks

• Risks and uncertainties that might cause actual results to differ materially from forward-looking statements.
• Ability to operate the business.
• Ability to study and develop Korlym, relacorilant, miricorilant, dazucorilant, nenocorilant, and other product candidates.
• Clinical attributes, regulatory approvals, mandates, oversight, and other requirements for these molecules.
• The scope and protective power of the company's intellectual property.

Future Outlook

Corcept Therapeutics projects full-year 2026 revenue to be between $900 million and $1,000 million, driven by continued expansion of its Cushing's syndrome business. The company anticipates FDA approval for relacorilant in platinum-resistant ovarian cancer by July 11, 2026, and EMA approval by the end of 2026. Key clinical trial results for MOMENTUM, BELLA Part A, and MONARCH are expected by the end of 2026, with a Phase 3 trial for dazucorilant in ALS planned to commence by mid-2026.

Management Comments

• "In 2025, our Cushing's syndrome business experienced a surge in demand due to growing recognition among physicians of hypercortisolism's true prevalence and the necessity of appropriate treatment. We had a record number of new prescriptions written for our medications and a record number of new prescribers in 2025, which translated to a 37 percent increase in the number of tablets sold compared to the prior year. We should have achieved higher growth but were not able to fully meet demand because of capacity constraints at our previous specialty pharmacy vendor. There were also operational disruptions in the fourth quarter as we transitioned our business to our new specialty pharmacy. This transition is now fully complete and February is on track to be a record month for the number of new patients that have started treatment with our medications. We expect that our Cushing's syndrome business will expand for many years." Joseph K. Belanoff, M.D., Corcept's Chief Executive Officer.
• "We are engaged with the FDA to determine the best path forward for our New Drug Application (NDA) for relacorilant in Cushing's syndrome and are confident that the ultimate outcome will be approval." Dr. Belanoff.
• "Our NDA for relacorilant in platinum-resistant ovarian cancer, which is now bolstered by the final overall survival results from our ROSELLA study, has a Prescription Drug User Fee Act (PDUFA) date of July 11, 2026." Dr. Belanoff.
• "Relacorilant has the potential to become the new standard of care for patients with Cushing's syndrome. In its Phase 2 and Phase 3 studies, patients treated with relacorilant showed clinically meaningful and statistically significant improvements in hypertension and a wide range of Cushing's syndrome's other signs and symptoms. Importantly, these benefits were observed without off-target effects and toxicities such as drug-induced hypokalemia, endometrial hypertrophy, vaginal bleeding, adrenal insufficiency and QT prolongation. These adverse events can have serious health consequences and are associated with currently available treatments. We are working with the FDA to bring relacorilant to patients as soon as possible." Bill Guyer, PharmD, Corcept's Chief Development Officer.
• "Results from our pivotal Phase 3 ROSELLA study demonstrate a 35 percent reduction in the risk of death in patients with platinum-resistant ovarian cancer (PROC). These results — without the need for biomarker selection, without increased safety burden and with oral administration — highlight relacorilant's potential to become the new standard of care in PROC. Our applications are under review with regulatory authorities in both the United States and Europe, and we are working with urgency to bring this medication to patients with this highly challenging form of ovarian cancer." Dr. Guyer.
• "Elevated cortisol activity is linked to ALS. In our Phase 2 DAZALS study, patients who received dazucorilant experienced a profound reduction in early mortality — a period when many patients with ALS retain significant function and quality of life." Dr. Guyer.

Industry Context

StockSavvy.ai notes that Corcept Therapeutics operates in the specialized and high-value segments of endocrinology and oncology, focusing on cortisol modulation. The company's strong revenue growth in its Cushing's syndrome business, despite supply chain challenges, indicates robust market demand for effective treatments in rare diseases. The advanced clinical pipeline, particularly with relacorilant in platinum-resistant ovarian cancer and dazucorilant in ALS, positions Corcept to potentially capture significant market share in areas with high unmet medical needs. The PDUFA date for relacorilant in ovarian cancer is a critical near-term catalyst, while the ongoing development in MASH and other cancers demonstrates a diversified approach to leveraging its cortisol modulation platform.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to global benchmarks.
• The 35% reduction in the risk of death observed in the ROSELLA study for relacorilant in platinum-resistant ovarian cancer is a significant clinical outcome, especially given the lack of biomarker selection and increased safety burden, which could differentiate it from existing or pipeline therapies in this challenging indication.
• The 84% reduction in the risk of death in the first year for dazucorilant (300mg) in ALS patients from the DAZALS study is a profound signal, potentially exceeding typical efficacy seen in ALS trials, which often show more modest benefits.
• The company's focus on cortisol modulation for a wide range of disorders, including rare endocrine conditions and various cancers, positions it uniquely compared to broader pharmaceutical companies, which may have less specialized pipelines.

Stakeholder Impact

• Shareholders: Potential for increased value due to strong revenue growth, positive 2026 guidance, and significant clinical pipeline progress, especially with multiple PDUFA dates and trial readouts. However, decreased net income and cash position in 2025 could be a concern.
• Patients (Cushing's syndrome): Improved access to medications as capacity constraints are resolved and new pharmacy transition is complete. Potential for a new standard of care with relacorilant.
• Patients (Ovarian Cancer, ALS, MASH, etc.): Hope for new treatment options with advanced clinical trials showing promising results (e.g., relacorilant in PROC, dazucorilant in ALS).
• Employees: Continued focus on R&D and commercial expansion suggests stable to growing employment opportunities.
• Suppliers/Vendors: Transition to a new specialty pharmacy indicates a change in vendor relationships, potentially impacting previous partners.

Next Steps

• Continue engagement with the FDA to determine the best path forward for relacorilant NDA in Cushing's syndrome.
• Prepare for the PDUFA date of July 11, 2026, for relacorilant in platinum-resistant ovarian cancer.
• Await EMA approval for relacorilant in platinum-resistant ovarian cancer by the end of 2026.
• Present MOMENTUM trial results at the ACC meeting in March.
• Present complete ROSELLA study results at the SGO meeting in April.
• Expect results from BELLA Part A and MONARCH trials by the end of 2026.
• Begin Phase 2 STELLA trial for relacorilant in cervical cancer in coming weeks.
• Start a Phase 3 trial of dazucorilant in ALS by mid-2026.
• Continue dose titration study for dazucorilant to improve gastrointestinal tolerability and inform Phase 3 program design.
• Broaden research to study glucocorticoid receptor antagonism in other solid tumor types.

Key Dates

Recommendation

While Corcept Therapeutics demonstrates strong revenue growth and a robust clinical pipeline with significant potential catalysts, the decline in net income and cash position in 2025, coupled with past operational disruptions and a Complete Response Letter for relacorilant in Cushing's syndrome, introduces a degree of uncertainty. The 2026 revenue guidance is positive, but investors should monitor the successful execution of the new pharmacy transition, the FDA approval process for relacorilant in ovarian cancer, and the upcoming clinical trial readouts. The stock is likely to experience volatility around these events, warranting a 'hold' position until further clarity on profitability trends and regulatory outcomes.

Keywords

Corcept Therapeutics, CORT, SEC Filing, Financial Results, Q4 2025, Full Year 2025, Revenue Guidance 2026, Cushing's Syndrome, Relacorilant, Ovarian Cancer, Platinum-Resistant Ovarian Cancer, MASH, Miricorilant, ALS, Dazucorilant, Clinical Trials, FDA Approval, PDUFA, Biotechnology, Pharmaceuticals, Endocrinology, Oncology, Metabolic Disorders, Neurologic Disorders, Cortisol Modulation, Drug Development